Imagine a world where life-saving medications are no longer out of reach for millions of Americans. That's the bold vision President Donald Trump is pushing with his latest move: expanding ‘Most Favored Nation’ (MFN) pricing deals to nine additional pharmaceutical giants. But here's where it gets controversial: while the White House hails this as a game-changer for drug affordability, experts are divided on whether it will truly deliver meaningful savings for patients. Let’s dive into the details and uncover what this could mean for you.
On Friday, Trump announced new voluntary agreements with major drugmakers, including Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi. These companies produce medications used by hundreds of millions of Americans to treat conditions like cancer, diabetes, and heart disease. The MFN program requires these firms to price their drugs in the U.S. at the lowest rates offered in comparable countries—a move Trump claims will slash costs dramatically. But is it enough?
And this is the part most people miss: While the deals sound promising, they currently cover only a fraction of the drugs available in the U.S., leaving many to wonder if the impact will be as significant as advertised. Plus, the agreements are voluntary, raising questions about long-term enforcement and industry commitment. A senior administration official boasted, ‘MFN has gone from a bold policy to an industry standard in record time,’ but critics argue the real test lies in tangible results for consumers.
Here’s how it works: Under the deals, drugmakers will sell medicines to Medicaid at MFN prices and launch new drugs in the U.S. at the same rate. They’ll also list certain medications on the upcoming TrumpRx platform, launching in January, which offers discounts to cash-paying customers bypassing insurance. Additionally, the companies have pledged over $150 billion in U.S. manufacturing and R&D investments, earning them a three-year tariff reprieve on pharmaceutical imports.
But there’s a catch. Some experts, like Chris Meekins of Raymond James, argue these deals are ‘largely inconsequential’ to drugmakers’ bottom lines, which is why they’re willing to participate. The TrumpRx portal might benefit those who can pay out of pocket, but for most Americans, insurance remains the cheaper route—except for certain medications like GLP-1 drugs (e.g., Wegovy and Zepbound), which are often not covered by insurers for weight loss. These drugs, priced at $1,000 to $1,350, will be available for as low as $149 per month under recent deals, though manufacturers like Eli Lilly and Novo Nordisk already offer steep discounts directly.
Here’s the burning question: Will these agreements truly lower drug costs for the average American, or are they more symbolic than substantive? Share your thoughts in the comments—do you think this is a step in the right direction, or is more radical reform needed? The debate is far from over.
